Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 26 entries
Sorted by: Best Match Show Resources per page
Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

Nature medicine

West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, Coccia M, Görtz D, This S, Stockenhuber K, Pott J, Friedrich M, Ryzhakov G, Baribaud F, Brodmerkel C, Cieluch C, Rahman N, Müller-Newen G, Owens RJ, Kühl AA, Maloy KJ, Plevy SE, Keshav S, Travis SPL, Powrie F.
PMID: 28586341
Nat Med. 2017 Jun 06;23(6):788. doi: 10.1038/nm0617-788d.

No abstract available.

Cite
West NR, Hegazy AN, Owens BMJ, et al. Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017;23(6):788doi: 10.1038/nm0617-788d.
West, N. R., Hegazy, A. N., Owens, B. M. J., Bullers, S. J., Linggi, B., Buonocore, S., Coccia, M., Görtz, D., This, S., Stockenhuber, K., Pott, J., Friedrich, M., Ryzhakov, G., Baribaud, F., Brodmerkel, C., Cieluch, C., Rahman, N., Müller-Newen, G., Owens, R. J., Kühl, A. A., Maloy, K. J., Plevy, S. E., Keshav, S., Travis, S. P. L., & Powrie, F. (2017). Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nature medicine, 23(6), 788. https://doi.org/10.1038/nm0617-788d
West, Nathaniel R, et al. "Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease." Nature medicine vol. 23,6 (2017): 788. doi: https://doi.org/10.1038/nm0617-788d
West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, Coccia M, Görtz D, This S, Stockenhuber K, Pott J, Friedrich M, Ryzhakov G, Baribaud F, Brodmerkel C, Cieluch C, Rahman N, Müller-Newen G, Owens RJ, Kühl AA, Maloy KJ, Plevy SE, Keshav S, Travis SPL, Powrie F. Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017 Jun 06;23(6):788. doi: 10.1038/nm0617-788d. PMID: 28586341.
Copy Download .nbib Format: NLM
Inhaled Steroids and Active Smoking Drive Chronic Obstructive Pulmonary Disease Symptoms and Biomarkers to a Greater Degree Than Airflow Limitation.

Biomarker insights

Silkoff PE, Singh D, FitzGerald JM, Eich A, Ludwig-Sengpiel A, Chupp GC, Backer V, Porsbjerg C, Girodet PO, Dransfield MT, Baribaud F, Susulic VS, Loza MJ.
PMID: 28959121
Biomark Insights. 2017 Sep 07;12:1177271917730306. doi: 10.1177/1177271917730306. eCollection 2017.

RATIONALE: Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease, and development of novel therapeutics requires an understanding of pathophysiologic phenotypes.OBJECTIVES: The purpose of the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study was to correlate clinical features and...

Cite
Silkoff PE, Singh D, FitzGerald JM, et al. Inhaled Steroids and Active Smoking Drive Chronic Obstructive Pulmonary Disease Symptoms and Biomarkers to a Greater Degree Than Airflow Limitation. Biomark Insights. 2017;12:1177271917730306doi: 10.1177/1177271917730306.
Silkoff, P. E., Singh, D., FitzGerald, J. M., Eich, A., Ludwig-Sengpiel, A., Chupp, G. C., Backer, V., Porsbjerg, C., Girodet, P. O., Dransfield, M. T., Baribaud, F., Susulic, V. S., & Loza, M. J. (2017). Inhaled Steroids and Active Smoking Drive Chronic Obstructive Pulmonary Disease Symptoms and Biomarkers to a Greater Degree Than Airflow Limitation. Biomarker insights, 121177271917730306. https://doi.org/10.1177/1177271917730306
Silkoff, Philip E, et al. "Inhaled Steroids and Active Smoking Drive Chronic Obstructive Pulmonary Disease Symptoms and Biomarkers to a Greater Degree Than Airflow Limitation." Biomarker insights vol. 12 (2017): 1177271917730306. doi: https://doi.org/10.1177/1177271917730306
Silkoff PE, Singh D, FitzGerald JM, Eich A, Ludwig-Sengpiel A, Chupp GC, Backer V, Porsbjerg C, Girodet PO, Dransfield MT, Baribaud F, Susulic VS, Loza MJ. Inhaled Steroids and Active Smoking Drive Chronic Obstructive Pulmonary Disease Symptoms and Biomarkers to a Greater Degree Than Airflow Limitation. Biomark Insights. 2017 Sep 07;12:1177271917730306. doi: 10.1177/1177271917730306. eCollection 2017. PMID: 28959121; PMCID: PMC5593220.
Copy Download .nbib Format: NLM
Integrating personalized gene expression profiles into predictive disease-associated gene pools.

NPJ systems biology and applications

Menche J, Guney E, Sharma A, Branigan PJ, Loza MJ, Baribaud F, Dobrin R, Barabási AL.
PMID: 28649437
NPJ Syst Biol Appl. 2017 Mar 13;3:10. doi: 10.1038/s41540-017-0009-0. eCollection 2017.

Gene expression data are routinely used to identify genes that

Cite
Menche J, Guney E, Sharma A, et al. Integrating personalized gene expression profiles into predictive disease-associated gene pools. NPJ Syst Biol Appl. 2017;3:10doi: 10.1038/s41540-017-0009-0.
Menche, J., Guney, E., Sharma, A., Branigan, P. J., Loza, M. J., Baribaud, F., Dobrin, R., & Barabási, A. L. (2017). Integrating personalized gene expression profiles into predictive disease-associated gene pools. NPJ systems biology and applications, 310. https://doi.org/10.1038/s41540-017-0009-0
Menche, Jörg, et al. "Integrating personalized gene expression profiles into predictive disease-associated gene pools." NPJ systems biology and applications vol. 3 (2017): 10. doi: https://doi.org/10.1038/s41540-017-0009-0
Menche J, Guney E, Sharma A, Branigan PJ, Loza MJ, Baribaud F, Dobrin R, Barabási AL. Integrating personalized gene expression profiles into predictive disease-associated gene pools. NPJ Syst Biol Appl. 2017 Mar 13;3:10. doi: 10.1038/s41540-017-0009-0. eCollection 2017. PMID: 28649437; PMCID: PMC5445628.
Copy Download .nbib Format: NLM
Tert-butylhydroquinone is a marker for sensitivity to Nigella sativa oil allergy: Five new cases.

Contact dermatitis

Seiller H, Kurihara F, Chasset F, Soria A, Barbaud A.
PMID: 33236781
Contact Dermatitis. 2021 Jun;84(6):447-449. doi: 10.1111/cod.13750. Epub 2020 Dec 20.

No abstract available.

Cite
Seiller H, Kurihara F, Chasset F, et al. Tert-butylhydroquinone is a marker for sensitivity to Nigella sativa oil allergy: Five new cases. Contact Dermatitis. 2020;84(6):447-449doi: 10.1111/cod.13750.
Seiller, H., Kurihara, F., Chasset, F., Soria, A., & Barbaud, A. (2021). Tert-butylhydroquinone is a marker for sensitivity to Nigella sativa oil allergy: Five new cases. Contact dermatitis, 84(6), 447-449. https://doi.org/10.1111/cod.13750
Seiller, Hélène, et al. "Tert-butylhydroquinone is a marker for sensitivity to Nigella sativa oil allergy: Five new cases." Contact dermatitis vol. 84,6 (2021): 447-449. doi: https://doi.org/10.1111/cod.13750
Seiller H, Kurihara F, Chasset F, Soria A, Barbaud A. Tert-butylhydroquinone is a marker for sensitivity to Nigella sativa oil allergy: Five new cases. Contact Dermatitis. 2021 Jun;84(6):447-449. doi: 10.1111/cod.13750. Epub 2020 Dec 20. PMID: 33236781.
Copy Download .nbib Format: NLM
[Alfuzosine-induced dermatomyositis] [In Process Citation].

Annales de dermatologie et de venereologie

Schmutz J, Barbaud A, Trechot P.
PMID: 10844271
Ann Dermatol Venereol. 2000 Apr;127(4):449.

No abstract available.

Cite
Schmutz J, Barbaud A, Trechot P. Alfuzosine, inducteur de dermatomyosite. [Alfuzosine-induced dermatomyositis] [In Process Citation]. Ann Dermatol Venereol. 2000;127(4):449
Schmutz, J., Barbaud, A., & Trechot, P. (2000). Alfuzosine, inducteur de dermatomyosite. [Alfuzosine-induced dermatomyositis] [In Process Citation]. Annales de dermatologie et de venereologie, 127(4), 449.
Schmutz, et al. "Alfuzosine, inducteur de dermatomyosite." [Alfuzosine-induced dermatomyositis] [In Process Citation]. Annales de dermatologie et de venereologie vol. 127,4 (2000): 449.
Schmutz J, Barbaud A, Trechot P. Alfuzosine, inducteur de dermatomyosite. [Alfuzosine-induced dermatomyositis] [In Process Citation]. Ann Dermatol Venereol. 2000 Apr;127(4):449. French. PMID: 10844271.
Copy Download .nbib Format: NLM
Longitudinally Stable, Clinically Defined Clusters of Patients with Asthma Independently Identified in the ADEPT and U-BIOPRED Asthma Studies.

Annals of the American Thoracic Society

Loza MJ, Adcock I, Auffray C, Chung KF, Djukanovic R, Sterk PJ, Susulic VS, Barnathan ES, Baribaud F, Silkoff PE.
PMID: 27027940
Ann Am Thorac Soc. 2016 Mar;13:S102-3. doi: 10.1513/AnnalsATS.201508-519MG.

BACKGROUND: ADEPT (Airways Disease Endotyping for Personalized Therapeutics) and U-BIOPRED (Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome Consortium) are independent asthma biomarker studies that aim to enable personalization of therapies.METHODS: Patients in both studies were identified by...

Cite
Loza MJ, Adcock I, Auffray C, et al. Longitudinally Stable, Clinically Defined Clusters of Patients with Asthma Independently Identified in the ADEPT and U-BIOPRED Asthma Studies. Ann Am Thorac Soc. 2016;13:S102-3doi: 10.1513/AnnalsATS.201508-519MG.
Loza, M. J., Adcock, I., Auffray, C., Chung, K. F., Djukanovic, R., Sterk, P. J., Susulic, V. S., Barnathan, E. S., Baribaud, F., Silkoff, P. E. (2016). Longitudinally Stable, Clinically Defined Clusters of Patients with Asthma Independently Identified in the ADEPT and U-BIOPRED Asthma Studies. Annals of the American Thoracic Society, 13S102-3. https://doi.org/10.1513/AnnalsATS.201508-519MG
Loza, Matthew J, et al. "Longitudinally Stable, Clinically Defined Clusters of Patients with Asthma Independently Identified in the ADEPT and U-BIOPRED Asthma Studies." Annals of the American Thoracic Society vol. 13 (2016): S102-3. doi: https://doi.org/10.1513/AnnalsATS.201508-519MG
Loza MJ, Adcock I, Auffray C, Chung KF, Djukanovic R, Sterk PJ, Susulic VS, Barnathan ES, Baribaud F, Silkoff PE. Longitudinally Stable, Clinically Defined Clusters of Patients with Asthma Independently Identified in the ADEPT and U-BIOPRED Asthma Studies. Ann Am Thorac Soc. 2016 Mar;13:S102-3. doi: 10.1513/AnnalsATS.201508-519MG. PMID: 27027940.
Copy Download .nbib Format: NLM
Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture.

Cancers

Bailly C, Bodet-Milin C, Bourgeois M, Gouard S, Ansquer C, Barbaud M, Sébille JC, Chérel M, Kraeber-Bodéré F, Carlier T.
PMID: 31480470
Cancers (Basel). 2019 Aug 31;11(9). doi: 10.3390/cancers11091282.

Personalized medicine represents a major goal in oncology. It has its underpinning in the identification of biomarkers with diagnostic, prognostic, or predictive values. Nowadays, the concept of biomarker no longer necessarily corresponds to biological characteristics measured ex vivo but...

Cite
Bailly C, Bodet-Milin C, Bourgeois M, et al. Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture. Cancers (Basel). 2019;11(9)doi: 10.3390/cancers11091282.
Bailly, C., Bodet-Milin, C., Bourgeois, M., Gouard, S., Ansquer, C., Barbaud, M., Sébille, J. C., Chérel, M., Kraeber-Bodéré, F., & Carlier, T. (2019). Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture. Cancers, 11(9), . https://doi.org/10.3390/cancers11091282
Bailly, Clément, et al. "Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture." Cancers vol. 11,9 (2019). doi: https://doi.org/10.3390/cancers11091282
Bailly C, Bodet-Milin C, Bourgeois M, Gouard S, Ansquer C, Barbaud M, Sébille JC, Chérel M, Kraeber-Bodéré F, Carlier T. Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture. Cancers (Basel). 2019 Aug 31;11(9). doi: 10.3390/cancers11091282. PMID: 31480470; PMCID: PMC6770004.
Copy Download .nbib Format: NLM
Nailfold capillaroscopy findings in cutaneous lupus erythematosus patients with or without digital lesions and comparison with dermatomyositis patients: A prospective study.

Lupus

Monfort JB, Chasset F, Barbaud A, Frances C, Senet P.
PMID: 33853419
Lupus. 2021 Jul;30(8):1207-1213. doi: 10.1177/09612033211010329. Epub 2021 Apr 15.

BACKGROUND: Differential diagnosis between cutaneous lupus erythematosus (CLE) and dermatomyositis (DM) may be challenging if digital lesions occur.OBJECTIVES: To compare nailfold capillaroscopy (NFC) findings in CLE patients with or without digital involvement, and to compare capillaroscopic findings between CLE...

Cite
Monfort JB, Chasset F, Barbaud A, et al. Nailfold capillaroscopy findings in cutaneous lupus erythematosus patients with or without digital lesions and comparison with dermatomyositis patients: A prospective study. Lupus. 2021;30(8):1207-1213doi: 10.1177/09612033211010329.
Monfort, J. B., Chasset, F., Barbaud, A., Frances, C., & Senet, P. (2021). Nailfold capillaroscopy findings in cutaneous lupus erythematosus patients with or without digital lesions and comparison with dermatomyositis patients: A prospective study. Lupus, 30(8), 1207-1213. https://doi.org/10.1177/09612033211010329
Monfort, Jean-Benoît, et al. "Nailfold capillaroscopy findings in cutaneous lupus erythematosus patients with or without digital lesions and comparison with dermatomyositis patients: A prospective study." Lupus vol. 30,8 (2021): 1207-1213. doi: https://doi.org/10.1177/09612033211010329
Monfort JB, Chasset F, Barbaud A, Frances C, Senet P. Nailfold capillaroscopy findings in cutaneous lupus erythematosus patients with or without digital lesions and comparison with dermatomyositis patients: A prospective study. Lupus. 2021 Jul;30(8):1207-1213. doi: 10.1177/09612033211010329. Epub 2021 Apr 15. PMID: 33853419.
Copy Download .nbib Format: NLM
Efficient and stable tin perovskite solar cells enabled by amorphous-polycrystalline structure.

Nature communications

Liu X, Wang Y, Wu T, He X, Meng X, Barbaud J, Chen H, Segawa H, Yang X, Han L.
PMID: 32472006
Nat Commun. 2020 May 29;11(1):2678. doi: 10.1038/s41467-020-16561-6.

Tin perovskite solar cells (TPSCs) have triggered intensive research as a promising candidate for lead-free perovskite solar cells. However, it is still challenging to obtain efficient and stable TPSCs because of the low defects formation energy and the oxidation...

Cite
Liu X, Wang Y, Wu T, et al. Efficient and stable tin perovskite solar cells enabled by amorphous-polycrystalline structure. Nat Commun. 2020;11(1):2678doi: 10.1038/s41467-020-16561-6.
Liu, X., Wang, Y., Wu, T., He, X., Meng, X., Barbaud, J., Chen, H., Segawa, H., Yang, X., & Han, L. (2020). Efficient and stable tin perovskite solar cells enabled by amorphous-polycrystalline structure. Nature communications, 11(1), 2678. https://doi.org/10.1038/s41467-020-16561-6
Liu, Xiao, et al. "Efficient and stable tin perovskite solar cells enabled by amorphous-polycrystalline structure." Nature communications vol. 11,1 (2020): 2678. doi: https://doi.org/10.1038/s41467-020-16561-6
Liu X, Wang Y, Wu T, He X, Meng X, Barbaud J, Chen H, Segawa H, Yang X, Han L. Efficient and stable tin perovskite solar cells enabled by amorphous-polycrystalline structure. Nat Commun. 2020 May 29;11(1):2678. doi: 10.1038/s41467-020-16561-6. PMID: 32472006; PMCID: PMC7260362.
Copy Download .nbib Format: NLM
Stabilizing heterostructures of soft perovskite semiconductors.

Science (New York, N.Y.)

Wang Y, Wu T, Barbaud J, Kong W, Cui D, Chen H, Yang X, Han L.
PMID: 31416961
Science. 2019 Aug 16;365(6454):687-691. doi: 10.1126/science.aax8018.

Here we report a solution-processing strategy to stabilize the perovskite-based heterostructure. Strong Pb-Cl and Pb-O bonds formed between a [CH(NH

Cite
Wang Y, Wu T, Barbaud J, et al. Stabilizing heterostructures of soft perovskite semiconductors. Science. 2019;365(6454):687-691doi: 10.1126/science.aax8018.
Wang, Y., Wu, T., Barbaud, J., Kong, W., Cui, D., Chen, H., Yang, X., & Han, L. (2019). Stabilizing heterostructures of soft perovskite semiconductors. Science (New York, N.Y.), 365(6454), 687-691. https://doi.org/10.1126/science.aax8018
Wang, Yanbo, et al. "Stabilizing heterostructures of soft perovskite semiconductors." Science (New York, N.Y.) vol. 365,6454 (2019): 687-691. doi: https://doi.org/10.1126/science.aax8018
Wang Y, Wu T, Barbaud J, Kong W, Cui D, Chen H, Yang X, Han L. Stabilizing heterostructures of soft perovskite semiconductors. Science. 2019 Aug 16;365(6454):687-691. doi: 10.1126/science.aax8018. PMID: 31416961.
Copy Download .nbib Format: NLM
Hydroxychloroquine dose tapering or discontinuation in cutaneous lupus erythematosus after remission: A retrospective multicenter cohort study of 56 patients.

Journal of the American Academy of Dermatology

Sonigo G, Jachiet M, Bessis D, Cordel N, Faucon C, Petit A, Cordoliani F, Bagot M, Senet P, Barbaud A, Bouaziz JD, Francès C, Chasset F.
PMID: 34333080
J Am Acad Dermatol. 2021 Jul 30; doi: 10.1016/j.jaad.2021.07.038. Epub 2021 Jul 30.

No abstract available.

Cite
Sonigo G, Jachiet M, Bessis D, et al. Hydroxychloroquine dose tapering or discontinuation in cutaneous lupus erythematosus after remission: A retrospective multicenter cohort study of 56 patients. J Am Acad Dermatol. 2021;doi: 10.1016/j.jaad.2021.07.038.
Sonigo, G., Jachiet, M., Bessis, D., Cordel, N., Faucon, C., Petit, A., Cordoliani, F., Bagot, M., Senet, P., Barbaud, A., Bouaziz, J. D., Francès, C., Chasset, F. (2021). Hydroxychloroquine dose tapering or discontinuation in cutaneous lupus erythematosus after remission: A retrospective multicenter cohort study of 56 patients. Journal of the American Academy of Dermatology, . https://doi.org/10.1016/j.jaad.2021.07.038
Sonigo, Gabrielle, et al. "Hydroxychloroquine dose tapering or discontinuation in cutaneous lupus erythematosus after remission: A retrospective multicenter cohort study of 56 patients." Journal of the American Academy of Dermatology vol. (2021). doi: https://doi.org/10.1016/j.jaad.2021.07.038
Sonigo G, Jachiet M, Bessis D, Cordel N, Faucon C, Petit A, Cordoliani F, Bagot M, Senet P, Barbaud A, Bouaziz JD, Francès C, Chasset F. Hydroxychloroquine dose tapering or discontinuation in cutaneous lupus erythematosus after remission: A retrospective multicenter cohort study of 56 patients. J Am Acad Dermatol. 2021 Jul 30; doi: 10.1016/j.jaad.2021.07.038. Epub 2021 Jul 30. PMID: 34333080.
Copy Download .nbib Format: NLM
Prevalence analysis of fungi in chronic lower extremity ulcers .

Wounds : a compendium of clinical research and practice

Foroozan M, Contet-Audonneau N, Granel-Brocard F, Barbaud A, Luc Schmutz J.
PMID: 25881333
Wounds. 2011 Mar;23(3):68-75.

UNLABELLED: Background. Lower extremity ulcers are a major cause of morbidity in elderly patients and can be colonized by many different microorganisms, including fungi. The purpose of this prospective study was to determine the prevalence of fungal colonization and/or...

Cite
Foroozan M, Contet-Audonneau N, Granel-Brocard F, et al. Prevalence analysis of fungi in chronic lower extremity ulcers . Wounds. 2011;23(3):68-75
Foroozan, M., Contet-Audonneau, N., Granel-Brocard, F., Barbaud, A., & Luc Schmutz, J. (2011). Prevalence analysis of fungi in chronic lower extremity ulcers . Wounds : a compendium of clinical research and practice, 23(3), 68-75.
Foroozan, Majid, et al. "Prevalence analysis of fungi in chronic lower extremity ulcers ." Wounds : a compendium of clinical research and practice vol. 23,3 (2011): 68-75.
Foroozan M, Contet-Audonneau N, Granel-Brocard F, Barbaud A, Luc Schmutz J. Prevalence analysis of fungi in chronic lower extremity ulcers . Wounds. 2011 Mar;23(3):68-75. PMID: 25881333.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 26 entries